You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海萊士(002252.SZ):人凝血酶原複合物獲批上市
格隆匯 07-16 16:19

格隆匯7月16日丨上海萊士(002252.SZ)公佈,公司全資子公司同路生物於近期收到國家藥監局簽發的關於人凝血酶原複合物的《藥品註冊證書》。

人凝血酶原複合物主要用於治療先天性和獲得性凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ缺乏症包括凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ缺乏症包括乙型血友病;抗凝劑過量、維生素K缺乏症;因肝病導致的凝血機制紊亂;播散性血管內凝血(DIC)時,凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ被大量消耗,可在肝素化後應用;各種原因所致的凝血酶原間延長而擬作外科手術患者,但對凝血因子Ⅴ缺乏者可能無效;治療已產生因子Ⅷ抑制物的甲型血友病患者的出血症狀;逆轉香豆素類抗凝劑誘導的出血。

公司表示,同路生物該次獲得人凝血酶原複合物的《藥品註冊證書》,是對同路生物產品的進一步補充,豐富了其產品線,有利於提升其原料血漿的綜合利用率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account